POP (pessary or surgery) and a composite of the two. Informed consent was obtained and surveys with validated questionnaires (PFDI-20, ISI, PISQ-IR, PGI-I) were used to assess pelvic floor symptoms, patient satisfaction and improvement. RESULTS: Three hundred thirty-three women met criteria. Mean age and BMI were 43 (+5.3) years and 27.9 (+5.8) kg/m 2 , respectively. The majority of women had a preoperative POP-Q stage of 2 (50.2%) or 3 (47.1%). A total of 29.1% (97) patients had an abdominal colpopexy and 70.9% (236) had a vaginal colpopexy. Patients who underwent abdominal colpopexy were more likely to have had a prior hysterectomy (20.6% vs 4.2%, p<.001) while the vaginal group was more likely to undergo concurrent hysterectomy and anterior repair (94.1% vs 78.4%, p<.001 and 66.5% vs 10.3%, p<.001, respectively). The composite recurrence rate was 32.0% (31) in the abdominal group and 24.2% (57) in the vaginal group (p¼.15), with a retreatment rate of 10.3% (10) in the abdominal group and 5.9% (14) in the vaginal group (p¼.16). The survey response rate was 45% (149) with a median response time of 2880 (1146-5540) days. The majority of patients (80.5%) reported prolapse improvement, which did not differ by colpopexy approach. However, more women in the abdominal group reported satisfaction with their surgery (100% vs 89.8%, p¼.02). 26.8% (40) of women complained of a pelvic floor symptom (pain, bowel and/or bladder) and this did not differ by colpopexy approach. The composite recurrence rate in respondents was 13.7% (7) in the abdominal group and 15.3% (15) in the vaginal group (p¼.80) with an overall retreatment rate of 5.9% (3) in the abdominal and 5.2% (5) in the vaginal group (p¼.85). CONCLUSION: For women 49 years of age, 1 in 3 will experience subjective POP recurrence and/or retreatment after apical prolapse surgery but only 5-10% will undergo retreatment. There does not appear to be a difference in the incidence of recurrence between the vaginal and abdominal routes of surgery. While 1 in 4 women report pelvic floor symptoms postoperatively, the majority report high satisfaction rates. Computer Science, Johns Hopkins University, Baltimore, MD OBJECTIVES: The objective in this study was to determine agreement between attending and trainee surgeons on important aspects of what happened in the operating room during robot-assisted laparoscopic hysterectomy (RALH) procedures, which are essential for teaching and assessment, e.g., case participation for accurate case logs, intraoperative skill assessment for performance evaluation and feedback.
2 , respectively. The majority of women had a preoperative POP-Q stage of 2 (50.2%) or 3 (47.1%). A total of 29.1% (97) patients had an abdominal colpopexy and 70.9% (236) had a vaginal colpopexy. Patients who underwent abdominal colpopexy were more likely to have had a prior hysterectomy (20.6% vs 4.2%, p<.001) while the vaginal group was more likely to undergo concurrent hysterectomy and anterior repair (94.1% vs 78.4%, p<.001 and 66.5% vs 10.3%, p<.001, respectively). The composite recurrence rate was 32.0% (31) in the abdominal group and 24.2% (57) in the vaginal group (p¼.15), with a retreatment rate of 10.3% (10) in the abdominal group and 5.9% (14) in the vaginal group (p¼.16). The survey response rate was 45% (149) with a median response time of 2880 (1146-5540) days. The majority of patients (80.5%) reported prolapse improvement, which did not differ by colpopexy approach. However, more women in the abdominal group reported satisfaction with their surgery (100% vs 89.8%, p¼.02). 26.8% (40) of women complained of a pelvic floor symptom (pain, bowel and/or bladder) and this did not differ by colpopexy approach. The composite recurrence rate in respondents was 13.7% (7) in the abdominal group and 15.3% (15) in the vaginal group (p¼.80) with an overall retreatment rate of 5.9% (3) in the abdominal and 5.2% (5) in the vaginal group (p¼.85). CONCLUSION: For women 49 years of age, 1 in 3 will experience subjective POP recurrence and/or retreatment after apical prolapse surgery but only 5-10% will undergo retreatment. There does not appear to be a difference in the incidence of recurrence between the vaginal and abdominal routes of surgery. While 1 in 4 women report pelvic floor symptoms postoperatively, the majority report high satisfaction rates. (91.3%) had a known history of anemia or heavy menstrual/ abnormal uterine bleeding. Eight women (4.1%) had elevated creatinine level (>1.0), seven of which had previously known renal disease or HTN/DM. Three patients (0.9%) underwent preoperative blood transfusion and eight patients (2.4%) received preoperative iron infusions. All patients who underwent preoperative blood transfusion or iron infusion, had symptomatic uterine fibroids and all but one had already known anemia. EKG was done for 102 (30%) of women and two patients (1.96%) required additional cardiology workup based on an abnormal EKG. Both patients had known hypertension and cardiac work up showed normal cardiac function that did not affect surgical management. T&S were collected on 273 (81%), of which five patients (1.5%) had a positive antibody screen, without their course of surgery being affected. Of the 336 identified cases, two surgeries (0.6%) were postponed, both in patients with previously known anemia who were found to have severe anemia (hemoglobin <7 g/dl) on preoperative testing. CONCLUSION: Routine preoperative testing was obtained in 93% of women undergoing minimally invasive gynecological surgery for benign indications. However, of the 77 patients who had an abnormality and/or underwent an intervention (blood transfusion, iron infusion, cardiology work-up or postponement or surgery), 70 (90.9%) had a previously known laboratory abnormality or condition. There may be little clinical utility in obtaining routine preoperative testing on patients without known preoperative conditions undergoing laparoscopic hysterectomy for benign indications, laparoscopic or hysteroscopic myomectomy or laparoscopic resection of endometriosis.
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